NextCure CMO Han Myint retires July 1; becomes consultant through 2025

NextCure, Inc.

Dr. Han Myint retires as CMO effective July 1, 2024; will provide consulting services starting July 2, 2024 on clinical trials and join Scientific Advisory Board.
The Company will provide continued salary and healthcare benefits through March 31, 2025.
Equity awards continue to vest during the consulting term; exercisability period extended to 90 days after term expiration.
Consulting agreement initial term through July 2, 2025, auto-renewing annually unless terminated by either party.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Han Myint

Chief Medical Officer

NXTC · NextCure, Inc.

Effective: 2024-07-01
Filed: June 18, 2024, 7:59 PM ET

Dr. Han Myint, M.D. notified NextCure, Inc. (the “Company”) of his plan to retire from his position as Chief Medical Officer of the Company, effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Han Myint retired as Chief Medical Officer at NextCure, Inc..

Action: retired
Role: Chief Medical Officer

Exact text from the filing

Dr. Han Myint, M.D. notified NextCure, Inc. (the “Company”) of his plan to retire from his position as Chief Medical Officer of the Company, effective July 1, 2024.

View on SEC.gov

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-009282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.